Skip to main content
a16z Podcast

Can America Win The AI Biotech Race Against China? | Lada Nuzhna & Elliot Hershberg

62 min episode · 2 min read
·

Episode

62 min

Read time

2 min

Topics

Artificial Intelligence

AI-Generated Summary

Key Takeaways

  • Can America compete with China's speed and cost advantages?
  • Will AI meaningfully reduce drug development costs and timelines?
  • What structural changes could revive biotech investment returns?
  • Where will the next trillion-dollar biotech companies emerge?

What It Covers

Lada Nuzhna and Elliot Hershberg analyze American biotech's competitive disadvantage against China, exploring regulatory barriers, AI's potential impact, and aging research opportunities.

Key Questions Answered

  • Can America compete with China's speed and cost advantages?
  • Will AI meaningfully reduce drug development costs and timelines?
  • What structural changes could revive biotech investment returns?
  • Where will the next trillion-dollar biotech companies emerge?

Notable Moment

Nuzhna reveals that George Yancopoulos paid ten thousand dollars per patient in Regeneron trials, while current costs have ballooned to five hundred thousand dollars per patient.

Know someone who'd find this useful?

You just read a 3-minute summary of a 59-minute episode.

Get a16z Podcast summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

More from a16z Podcast

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Business Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's AI & Machine Learning Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into a16z Podcast.

Every Monday, we deliver AI summaries of the latest episodes from a16z Podcast and 192+ other podcasts. Free for up to 3 shows.

Start My Monday Digest

No credit card · Unsubscribe anytime